Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 20;64(4):636–645. doi: 10.1136/gutjnl-2013-306620

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

PMC Copyright notice

Identification of a five-gene signature (CDH10, COL6A3, SMAD4, TMEM132D, VCAN) that was associated with significantly better overall survival in patients with CRC. Mutation frequency of individual composing genes was ≥5% in our CRC cohort. (A) Kaplan-Meier survival analysis showed that patients with mutation(s) in at least one composing gene of this signature had significantly longer overall survival than those patients with wild type genotype (median survival 80.4 months vs 42.4 months; p=0.005). (B), Subgroup analysis in patients with stage I+II CRC confirmed the prognostic value of this five-gene signature in early stage CRC. (C) The prognostic significance of this five-gene signature was verified in an independent cohort by extracting mutation and survival data from The Cancer Genome Atlas (TCGA) study. (D) The five-gene signature readily differentiated patients with dissimilar survival outcomes in stage I+II CRC in TCGA cohort. (E), The five-gene signature was significantly associated with survival in microsatellite-stable (MSS) patients (Asian+TCGA cohorts), suggesting that survival advantage of signature-mutant patients was not conferred by MSI.